MedTrace Logo

A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Under the Age of 6 Years

NCT02263469 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2014-10-13

No results posted yet for this study

Summary

The objective of this study was to assess the safety and efficacy of Replenine®-VF in children enrolled in the study, under the age of six years, with severe haemophilia B.

Conditions

  • Haemophilia B

Interventions

BIOLOGICAL

Replenine®-VF (High Purity Factor IX)

Sponsors & Collaborators

  • Bio Products Laboratory

    lead OTHER

Eligibility

Max Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2006-07-31

Countries

  • Poland
  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02263469 on ClinicalTrials.gov